Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Downgraded to 3, from 8…. With everything going on?!?

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Jul 29, 2021 10:34am

143 Views

Post# 33620667

RE:RE:RE:Downgraded to 3, from 8…. With everything going on?!?

Yawn...Eddie only cares about NASH and isn't broad enough to add in other biotechs or cover oncology. His industry is in the doldrums and now NASH is further off and Cantor, who gets the oncology side, jumped in and has actual clients -they are now banking front runners. He was clueless on cancer developments. His firm is being sold and he needs to figure out a new future. But it is one more broker they've managed to piss off.